Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
15/07/26	CN¥6.720	+2.75%	35,433,950
14/07/26	CN¥6.540	+2.19%	24,122,100
13/07/26	CN¥6.400	+2.24%	28,045,834
10/07/26	CN¥6.260	+2.79%	15,588,946
09/07/26	CN¥6.090	-0.65%	11,289,800

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shanghai S.E. Other stock markets 14/07/2026			5-day change	1st Jan Change
6.540 ^CNY	+2.19%		+6.69%	+0.77%

05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	4.65B 687M 600M 555M 512M 965M 65.95B 983M 6.61B 2.6B 32.29B 2.58B 2.52B 111B	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	3.87B 571M 499M 461M 426M 802M 54.83B 817M 5.5B 2.16B 26.85B 2.14B 2.1B 92.44B	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.86%	Yield 2024	4.93%	Yield 2025	5.39%

05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12-21	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
12-18	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
11-17	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
11-13	Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 17, 2025, has closed with 8,000,000 shares, representing 1.14% for CNY 52.15 million.	CI
11-13	Yabao Pharmaceutical Obtains Registration for Children's Nutrition Product	MT
24/10/25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/10/25	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
24/09/25	Yabao Pharmaceutical Gets Nod to Trial Asthma Drug for Children	MT
23/09/25	Yabao Pharmaceutical Ends Trial for Diabetes Drug; Shares Down 3%	MT
15/08/25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI

30/06/16	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
20/04/16	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
12/01/16	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
20/10/15	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15/09/15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Share Price

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation: Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news : Yabao Pharmaceutical Group Co., Ltd

Press Releases: Yabao Pharmaceutical Group Co., Ltd

News in other languages: Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+2.19%
1 week	+6.69%
Current month	+13.74%
1 month	+3.97%
6 months	-2.68%
Current year	+0.77%

1 week	6	6.54
1 month	5.6	6.54
Current year	5.6	7.19
1 year	5.6	8.68
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	22/04/2019
Zhe Feng Zuo DFI	Director of Finance/CFO	54	16/05/2017
Peng Bo Ren PRN	Corporate Officer/Principal	53	10/03/2007

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	25/05/2005
Min Xuan Cui BRD	Director/Board Member	66	15/06/2020
Peng Bo Ren BRD	Director/Board Member	53	14/05/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+2.19%	+6.69%	+3.15%	-7.37%	668M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.46%	+3.35%	+12.97%	+81.10%	48.52B
OTSUKA HOLDINGS CO., LTD.	-0.36%	-4.82%	+65.56%	+115.03%	35.68B
CIPLA LIMITED	-0.01%	+0.43%	-3.55%	+39.25%	12.09B
ZYDUS LIFESCIENCES LIMITED	+2.06%	+0.78%	+19.56%	+91.84%	11.77B
KRKA, D. D.	+1.13%	+0.38%	+32.83%	+126.50%	9.19B
ONO PHARMACEUTICAL CO., LTD.	-1.81%	-2.85%	+45.77%	-5.83%	7.06B
GEDEON RICHTER	-0.67%	-0.50%	+18.32%	+36.88%	7.01B
GLENMARK PHARMACEUTICALS LIMITED	-0.33%	+3.31%	+3.20%	+227.08%	6.77B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+6.39%	-0.15%	-14.91%	+20.63%	5.98B
Average	+0.90%	+1.05%	+18.29%	+72.51%	14.47B
Weighted average by Cap.	+0.44%	-0.24%	+26.55%	+87.26%

	2024	2025
Net sales	2.69B 397M 347M 320M 296M 557M 38.09B 568M 3.82B 1.5B 18.65B 1.49B 1.46B 64.23B	2.24B 331M 289M 267M 247M 465M 31.77B 473M 3.19B 1.25B 15.56B 1.24B 1.21B 53.56B
Net income	243M 35.83M 31.31M 28.95M 26.74M 50.36M 3.44B 51.28M 345M 135M 1.69B 135M 132M 5.8B	320M 47.25M 41.29M 38.17M 35.27M 66.41M 4.54B 67.61M 455M 179M 2.22B 177M 174M 7.65B
Net Debt	-483M -71.3M -62.31M -57.6M -53.21M -100M -6.85B -102M -687M -270M -3.35B -268M -262M -11.55B	-784M -116M -101M -93.56M -86.44M -163M -11.12B -166M -1.12B -438M -5.45B -435M -425M -18.76B